Peking Union Medical College Hospital
Peking Union Medical College Hospital
Beijing, China62 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Not applicable | 2026-10-08 | NCT07866612 | |
| Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension | lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT04273945 | |
| A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam | central nervous system disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Recruiting | Phase 3 | 2026-10-02 | NCT07444476 | |
| A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | interstitial lung disease, lung disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT06806592 | |
| A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 2 | 2026-10-01 | NCT07409181 | |
| The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | bronchial disorder, bronchiectasis, respiratory system disorder | Recruiting | Phase 3 | 2026-10-01 | NCT06872892 | |
| A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | acquired idiopathic inflammatory myopathy, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease | Not yet recruiting | Phase 3 | 2026-09-30 | NCT07789015 | |
| A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis | Skin and Connective Tissue Diseases, connective tissue disorder, skin disorder, systemic sclerosis | Recruiting | Phase 3 | 2026-09-30 | NCT07497087 | |
| A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-09-30 | NCT06238622 | |
| An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | neoplasm | Active, not recruiting | Phase 3 | 2026-09-30 | NCT05112965 | |
| A Study of Guselkumab in Participants With Active Psoriatic Arthritis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT04882098 | |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | Urothelial Cancer | Active, not recruiting | Phase 3 | 2026-09-25 | NCT03390504 | |
| [18F]FIDT-10b PET Imaging in Cardiac Amyloidosis | Light Chain Cardiac Amyloidosis; Transthyretin Cardiac Amyloidosis | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-23 | NCT07835880 | |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-22 | NCT06712316 | |
| Beta-amyloid PET/CT to Measure Potential Therapeutic Response in AL-CA | Light Chain Cardiac Amyloidosis | Recruiting | Phase 2 | 2026-09-21 | NCT07829705 | |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy | Skin and Connective Tissue Diseases, antisynthetase syndrome, connective tissue disorder, dermatomyositis, immune-mediated necrotizing myopathy, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, polymyositis, skin disorder | Enrolling by invitation | Phase 3 | 2026-09-21 | NCT05979441 | |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2026-09-01 | NCT06712355 | |
| Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract disorder, neoplasm | Recruiting | Phase 2 | 2026-08-26 | NCT07786766 | |
| A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies | Skin and Connective Tissue Diseases, connective tissue disorder, dermatomyositis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, polymyositis, skin disorder | Recruiting | Phase 3 | 2026-08-25 | NCT06698796 | |
| A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors | Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria | Active, not recruiting | Phase 3 | 2026-08-18 | NCT04434092 | |
| SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Not yet recruiting | Phase 2 | 2026-07-31 | NCT07738757 | |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-07-02 | NCT06578247 | |
| Risk Factor Assessment for Acute Pulmonary Hypertension Crisis | Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, disease, hypertensive disorder, lung disorder, pulmonary hypertension, respiratory system disorder, vascular disorder | Recruiting | Not stated | 2026-06-22 | NCT07653958 | |
| Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery | Neurobehavioral Manifestations, Neurologic Manifestations, Pain, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Postoperative Pain, Signs and Symptoms, Spinal Curvatures, agnosia, bone disorder, musculoskeletal system disorder, nervous system disorder, perceptual disorders, scoliosis, vertebral column disorder | Not yet recruiting | Phase 4 | 2026-06-17 | NCT07229495 | |
| Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, cone-rod dystrophy, eye disorder, hereditary disease, inherited retinal dystrophy, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder, retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome, uveal disorder, uveitis | Recruiting | Phase 1 | 2026-06-05 | NCT06395285 |